Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Remitly Global Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Remitly Global Inc trades at $23.49 (market cap $5.03B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 2,682,448). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Remitly Global Inc for 53 Days on average.
| KYMR | RELY | |
|---|---|---|
Market Cap | $8.87B | $5.03B |
Volume | 779,107 | 2,682,448 |
Sector | Health | Technology |
52-Week High | $127.31 | $26.92 |
52-Week Low | $55.80 | $12.20 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $8.26B | $4.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RELY trades at $23.49, showing modest daily movement with strong technical momentum. The company demonstrates accelerating revenue growth, reaching $1.64 billion in 2025 with improving profitability margins. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.93 significantly exceeding the $0.12 forecast. Analyst sentiment remains overwhelmingly positive with 92% buy ratings and a $30.50 consensus price target, representing 30% upside potential from current levels.
The outlook remains bullish given strong fundamentals and growth trajectory, though the stock faces risks from competitive pressures and potential market volatility. RELY's transition to profitability and expanding customer base to over 10 million active users supports continued upside, while elevated valuation multiples require sustained execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
